How to manage diabetes in dialysis patients?

Journal of Nephrology & Therapeutics

ISSN: 2161-0959

Open Access

How to manage diabetes in dialysis patients?

13th World Nephrology Conference

October 18-19, 2017 Dubai, UAE

Fakhriya Alalawi

Dubai Health Authority, UAE

Scientific Tracks Abstracts: J Nephrol Ther

Abstract :

The incidence and prevalence of diabetes mellitus have grown significantly throughout the world, primarily due to the increased incidence of type-2 diabetes. This overall increase in the number of individuals with diabetes has had a major impact on development of diabetic kidney disease (DKD). Diabetic kidney disease (DKD) affects approximately 20-40% of diabetic patients prompting to ESRD, making it one of the major and increasing global public health issues. Managing diabetic patients on hemodialysis is challenging, as both uremia and dialysis can complicate glycemic control by affecting the secretion, clearance and peripheral tissue sensitivity of insulin. Moreover, dialysis patients are at increased risk of hypoglycemia due to decreased clearance of insulin, poor nutritional intake; decreased hepatic gluconeogenesis and altered pharmacokinetics of glucose-lowering drugs by kidney failure while the conventional methods of glycemic monitoring (as glycated hemoglobin (HbA1c), fructoasmine and glycated albumin) are confounded by the laboratory abnormalities and co-morbidities related to ESRD. There are a number of controversies regarding the current management of diabetic patients maintained on hemodialysis. Generally, diabetes control should be optimized for each individual patient, in order to reduce diabetes-related complications, minimize adverse events and to increase survival rates among diabetic dialysis patients. However, the role of tight glycemic control in ameliorating the high mortality risk of diabetic dialysis patients is uncertain and does not appear to improve the outcomes in such population. Ultimately, many glucose-lowering drugs with their active metabolites are metabolized and excreted through the kidneys; hence require dose adjustment or avoidance in dialysis patients.

Biography :

Fakhriya Alalawi is a Senior Nephrologist in Dubai Hospital, Dubai Health Authority, UAE. She has received her Medical Bachelor’s degree from Dubai Medical College and her Residency in Internal Medicine and Nephrology in Dubai, UAE. She has also obtained her MRCP (UK) and SCE (UK) in Nephrology. She is a Fellow of American Society of Nephrology (FASN) and Fellow of the Royal College of Physicians of London (FRCP). She is interested in medical education as well as public awareness of kidney disease and she had conducted different clinical audits and has many publications in various nephrology journals.

Google Scholar citation report
Citations: 784

Journal of Nephrology & Therapeutics received 784 citations as per Google Scholar report

Journal of Nephrology & Therapeutics peer review process verified at publons

Indexed In

arrow_upward arrow_upward